Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, discusses the potential of ...

When Mags Kirwan was first diagnosed with multiple myeloma three years ago, she made the conscious decision to “run her own ...

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

A Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...